| Stacy Lynn Turner, APRN FNP-C | |
|
78 Highway 3444, Annville, KY 40402-8245 | |
| (606) 364-5162 | |
| (606) 364-3920 |
| Full Name | Stacy Lynn Turner |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 78 Highway 3444, Annville, Kentucky |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053719310 | NPI | - | NPPES |
| 7100326810 | Medicaid | KY |
| Entity Name | David J Hays |
|---|---|
| Entity Type | Practitioner - Family Practice |
| Entity Identifiers | NPI Number: 1215929997 PECOS PAC ID: 6305740424 Enrollment ID: I20091120000073 |
News Archive
The Cost Of Uncompensated Care With And Without Health Reform - This report analyzes various health bills. "The cost of uncompensated care will fall from $62.1 billion in 2009 to $46.6 billion in 2019 under the Senate bill, and to $36.5 billion in 2019 with the House bill. Without reform, the cost of uncompensated care will increase to between $107 and $141 billion in 2019, depending on growth in the economy and health care costs.
Using intensive treatment to lower blood pressure below currently recommended targets significantly reduces rates of major cardiovascular events like stroke and heart attack among a wide range of high-risk patients, according to a large meta-analysis involving almost 45000 individuals, published in The Lancet.
Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.
Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.
› Verified 1 days ago
| Entity Name | Arthritis And Osteoporosis Center Of Kentucky Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1962647297 PECOS PAC ID: 2668536350 Enrollment ID: O20090124000012 |
News Archive
The Cost Of Uncompensated Care With And Without Health Reform - This report analyzes various health bills. "The cost of uncompensated care will fall from $62.1 billion in 2009 to $46.6 billion in 2019 under the Senate bill, and to $36.5 billion in 2019 with the House bill. Without reform, the cost of uncompensated care will increase to between $107 and $141 billion in 2019, depending on growth in the economy and health care costs.
Using intensive treatment to lower blood pressure below currently recommended targets significantly reduces rates of major cardiovascular events like stroke and heart attack among a wide range of high-risk patients, according to a large meta-analysis involving almost 45000 individuals, published in The Lancet.
Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.
Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.
› Verified 1 days ago
| Entity Name | Fuse Medical |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164003125 PECOS PAC ID: 5294134938 Enrollment ID: O20210528001137 |
News Archive
The Cost Of Uncompensated Care With And Without Health Reform - This report analyzes various health bills. "The cost of uncompensated care will fall from $62.1 billion in 2009 to $46.6 billion in 2019 under the Senate bill, and to $36.5 billion in 2019 with the House bill. Without reform, the cost of uncompensated care will increase to between $107 and $141 billion in 2019, depending on growth in the economy and health care costs.
Using intensive treatment to lower blood pressure below currently recommended targets significantly reduces rates of major cardiovascular events like stroke and heart attack among a wide range of high-risk patients, according to a large meta-analysis involving almost 45000 individuals, published in The Lancet.
Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.
Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stacy Lynn Turner, APRN FNP-C 78 Highway 3444, Ste 1, Annville, KY 40402-8245 Ph: (859) 623-5500 | Stacy Lynn Turner, APRN FNP-C 78 Highway 3444, Annville, KY 40402-8245 Ph: (606) 364-5162 |
News Archive
The Cost Of Uncompensated Care With And Without Health Reform - This report analyzes various health bills. "The cost of uncompensated care will fall from $62.1 billion in 2009 to $46.6 billion in 2019 under the Senate bill, and to $36.5 billion in 2019 with the House bill. Without reform, the cost of uncompensated care will increase to between $107 and $141 billion in 2019, depending on growth in the economy and health care costs.
Using intensive treatment to lower blood pressure below currently recommended targets significantly reduces rates of major cardiovascular events like stroke and heart attack among a wide range of high-risk patients, according to a large meta-analysis involving almost 45000 individuals, published in The Lancet.
Peregrine Pharmaceuticals, Inc. has announced that the U.S. Patent and Trademark Office has issued U.S. Patent Number No. 7,455,833, which includes broad claims covering anti-viral applications of antibodies that directly bind to aminophospholipids.
Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.
› Verified 1 days ago